Thermo Fisher Scientific (NYSE:TMO) reported fourth-quarter results that topped market expectations, lifting its shares in premarket trading on Thursday as investors welcomed stronger earnings and revenue growth.
The medical equipment and life sciences group posted earnings per share of $6.57, ahead of the $6.45 anticipated by analysts. Quarterly revenue increased 7% year on year to $12.21 billion, comfortably exceeding the consensus estimate of $11.89 billion. The company said organic revenue growth for the quarter came in at 3%.
Thermo Fisher’s shares were up 1.4% in premarket trading by 06:08 ET.
“Thanks to our exceptional team, we delivered a strong finish to 2025, reflecting outstanding execution and the continued strength of our proven growth strategy,” said Marc Casper, chairman, president and CEO of Thermo Fisher Scientific. “We enter 2026 from a position of strength. Our growth strategy is resonating with customers, positioning us for continued share gain, and our PPI Business System provides a strong foundation to continue our excellent operational performance.”
Adjusted operating income for the fourth quarter of 2025 rose 6% from a year earlier to $2.88 billion, while the adjusted operating margin edged slightly lower to 23.6% from 23.9% in the prior-year period.
The company said it will provide its financial outlook for 2026 during its earnings conference call, scheduled for 8:30 a.m. ET.